N-Glycolylneuraminic acid deficiency worsens cardiac and skeletal muscle pathophysiology in α-sarcoglycan-deficient mice

Glycobiology

Volumn 23, Issue 7, 2013, Pages 833-843

  Martin, Paul T ^a,b   Camboni, Marybeth ^a   Xu, Rui ^a   Golden, Bethannie ^a   Chandrasekharan, Kumaran ^a   Wang, Chiou Miin ^a   Varki, Ajit ^c   Janssen, Paul M L ^b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

dystroglycan; limb girdle; muscular dystrophy; sarcoglycan; sialic acid

Indexed keywords

ALPHA SARCOGLYCAN; CREATINE KINASE; CYTIDINE 5 MONOPHOSPHO NEU5AC HYDROXYLASE; N GLYCOLOYLNEURAMINIC ACID; OXYGENASE; TRANSCRIPTION FACTOR PAX7; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CELLS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIAPHRAGM; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVITY; GASTROCNEMIUS MUSCLE; GENE DELETION; GENE EXPRESSION; GENE LOSS; HEART MUSCLE; LIMB GIRDLE MUSCULAR DYSTROPHY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; SKELETAL MUSCLE; SMOOTH MUSCLE; TIBIALIS ANTERIOR MUSCLE;

DYSTROGLYCAN; LIMB GIRDLE; MUSCULAR DYSTROPHY; SARCOGLYCAN; SIALIC ACID;

ANIMALS; GENE DELETION; HUMANS; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; NEURAMINIC ACIDS; SARCOGLYCANS;

EID: 84882750890     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt020     Document Type: Article

References (40)

1. Bardor M, Nguyen DH, Diaz S, Varki A. 2005. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem. 280:4228-4237.
2. Bennett E, Urcan MS, Tinkle SS, Koszowski AG, Levinson SR. 1997. Contribution of sialic acid to the voltage dependence of sodium channel gating. A possible electrostatic mechanism. J Gen Physiol. 109:327-343.
3. Chandrasekharan K, Yoon JH, Xu Y, deVries S, Camboni M, Janssen PM, Varki A, Martin PT. 2010. A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci Transl Med. 2:42-54.
4. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A. 1998. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA. 95:11751-11756.
5. Diaz SL, Padler-Karavani V, Ghaderi D, Hurtado-Ziola N, Yu H, Chen X, Brinkman-Van der Linden EC, Varki A, Varki NM. 2009. Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS One. 4:e4241.
6. Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J,, et al. 1998. Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol. 142:1461-1471.
7. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash M, Shemesh M, Sadeh M, Grabov-Nardini G,, et al. 2001. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet. 29:83-87.
8. Fermini B, Nathan RD. 1991. Removal of sialic acid alters both T- and L-type calcium currents in cardiac myocytes. Am J Physiol. 260:H735-H743.
9. Ferreira AF, Carvalho MS, Resende MB, Wakamatsu A, Reed UC, Marie SK. 2011. Phenotypic and immunohistochemical characterization of sarcoglycanopathies. Clinics (Sao Paulo). 66:1713-1719.
10. Freeze HH. 2006. Genetic defects in the human glycome. Nat Rev Genet. 7:537-551.
11. Godfrey C, Foley AR, Clement E, Muntoni F. 2011. Dystroglycanopathies: Coming into focus. Curr Opin Genet Dev. 21:278-285.
12. Guglieri M, Straub V, Bushby K, Lochmuller H. 2008. Limb-girdle muscular dystrophies. Curr Opin Neurol. 21:576-584.
13. Hedlund M, Padler-Karavani V, Varki NM, Varki A. 2008. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci USA. 105:18936-18941.
14. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL,, et al. 2007. N-glycolylneuraminic acid deficiency in mice: Implications for human biology and evolution. Mol Cell Biol. 27:4340-4346.
15. Hoffman EP, Brown RH, Jr., Kunkel LM. 1987. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:919-928.
16. Hoyte K, Jayasinha V, Xia B, Martin PT. 2004. Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice. Am J Pathol. 164:711-718.
17. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A. 1998. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem. 273:15866-15871.
18. Janssen PM. 2010. Myocardial contraction-relaxation coupling. Am J Physiol Heart Circ Physiol. 299:H1741-H1749.
19. Kawano T, Koyama S, Takematsu H, Kozutsumi Y, Kawasaki H, Kawashima S, Kawasaki T, Suzuki A. 1995. Molecular cloning of cytidine monophospho-N- acetylneuraminic acid hydroxylase. Regulation of speciesand tissue-specific expression of N-glycolylneuraminic acid. J Biol Chem. 270:16458-16463.
20. Malykh YN, Schauer R, Shaw L. 2001. N-Glycolylneuraminic acid in human tumours. Biochimie. 83:623-634.
21. Martin PT. 2005. The dystroglycanopathies: the new disorders of O-linked glycosylation. Semin Pediatr Neurol. 12:152-158.
22. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, et al. 2002. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature. 418:417-422.
23. Miller G, Wang EL, Nassar KL, Peter AK, Crosbie RH. 2007. Structural and functional analysis of the sarcoglycan-sarcospan subcomplex. Exp Cell Res. 313:639-651.
24. Murray JD, Canan BD, Martin CD, Stangland JE, Rastogi N, Rafael-Fortney JA, Janssen PM. 2012. The force-temperature relationship in healthy and dystrophic mouse diaphragm; implications for translational study design. Front Physiol. 3:422.
25. Nguyen HH, Jayasinha V, Xia B, Hoyte K, Martin PT. 2002. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA. 99:5616-5621.
26. Padler-Karavani V, Yu H, Cao H, Chokhawala H, Karp F, Varki N, Chen X, Varki A. 2008. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology. 18:818-830.
27. Recio-Pinto E, Thornhill WB, Duch DS, Levinson SR, Urban BW. 1990. Neuraminidase treatment modifies the function of electroplax sodium channels in planar lipid bilayers. Neuron. 5:675-684.
28. Schwarzkopf M, Knobeloch KP, Rohde E, Hinderlich S, Wiechens N, Lucka L, Horak I, Reutter W, Horstkorte R. 2002. Sialylation is essential for early development in mice. Proc Natl Acad Sci USA. 99:5267-5270.
29. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. 2000. Pax7 is required for the specification of myogenic satellite cells. Cell. 102:777-786.
30. Shaw L, Schneckenburger P, Carlsen J, Christiansen K, Schauer R. 1992. Mouse liver cytidine-5′-monophosphate-N-acetylneuraminic acid hydroxylase. Catalytic function and regulation. Eur J Biochem. 206:269-277.
31. Straub V, Bushby K. 2006. The childhood limb-girdle muscular dystrophies. Semin Pediatr Neurol. 13:104-114.
32. Sveen ML, Thune JJ, Kober L, Vissing J. 2008. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. Arch Neurol. 65:1196-1201.
33. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA. 100:12045-12050.
34. Taylor RE, Gregg CJ, Padler-Karavani V, Ghaderi D, Yu H, Huang S, Sorensen RU, Chen X, Inostroza J, Nizet V, et al. 2010. Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid N-glycolylneuraminic acid. J Exp Med. 207:1637-1646.
35. Varki A. 2010. Colloquium paper: Uniquely human evolution of sialic acid genetics and biology. Proc Natl Acad Sci USA. 107(Suppl 2):8939-8946.
36. Wang YX, Rudnicki MA. 2012. Satellite cells, the engines of muscle repair. Nat Rev Mol Cell Biol. 13:127-133.
37. Xu R, Camboni M, Martin PT. 2007. Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: Evidence for a utrophin-independent mechanism. Neuromuscul Disord. 17:209-220.
38. Xu R, Chandrasekharan K, Yoon JH, Camboni M, Martin PT. 2007. Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A. Am J Pathol. 171:181-199.
39. Xu R, DeVries S, Camboni M, Martin PT. 2009. Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycandeficient mice. Am J Pathol. 175:235-247.
40. Yoon JH, Chandrasekharan K, Xu R, Glass M, Singhal N, Martin PT. 2009. The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin. Mol Cell Neurosci. 41:448-463.